SLAM receptors foster iNKT cell development by reducing TCR signal strength after positive selection.


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
04 2019
Historique:
received: 16 08 2018
accepted: 25 01 2019
pubmed: 6 3 2019
medline: 20 4 2019
entrez: 6 3 2019
Statut: ppublish

Résumé

Invariant natural killer T cells (iNKT cells) develop through an incompletely understood process that requires positive selection by CD4

Identifiants

pubmed: 30833791
doi: 10.1038/s41590-019-0334-0
pii: 10.1038/s41590-019-0334-0
doi:

Substances chimiques

Costimulatory and Inhibitory T-Cell Receptors 0
Proto-Oncogene Proteins c-bcl-2 0
Receptors, Antigen, T-Cell 0
SLAMF6 protein, human 0
Sh2d1a protein, mouse 0
Signaling Lymphocytic Activation Molecule Associated Protein 0
Signaling Lymphocytic Activation Molecule Family 0
Slamf6 protein, mouse 0
Proto-Oncogene Proteins c-fyn EC 2.7.10.2
Protein Tyrosine Phosphatase, Non-Receptor Type 6 EC 3.1.3.48
Ptpn6 protein, mouse EC 3.1.3.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-457

Commentaires et corrections

Type : CommentIn

Auteurs

Yan Lu (Y)

Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal, Montréal, Québec, Canada.

Ming-Chao Zhong (MC)

Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal, Montréal, Québec, Canada.

Jin Qian (J)

Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal, Montréal, Québec, Canada.

Virginie Calderon (V)

Bioinformatics Core Facility, Institut de recherches cliniques de Montréal, Montréal, Québec, Canada.

Mayra Cruz Tleugabulova (M)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Thierry Mallevaey (T)

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Institute of Biomaterials & Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.

André Veillette (A)

Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal, Montréal, Québec, Canada. andre.veillette@ircm.qc.ca.
Department of Medicine, University of Montréal, Montréal, Québec, Canada. andre.veillette@ircm.qc.ca.
Department of Medicine, McGill University, Montréal, Québec, Canada. andre.veillette@ircm.qc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH